The company presented the preliminary findings of its Phase I/II trial to colleagues at the International Society for Cell and Gene Therapy conference.
The presentation happened in New Orleans last week and results were shared in a statement released to the Tel Aviv Stock Exchange.
Bonus BioGroup’s MesenCure, consists of activated Mesenchymal Stromal Cells (MSCs) that are isolated from the adipose tissue of healthy donors.
Experts found out that the drug reduces inflammation and alleviates respiratory and other symptoms in patients suffering from respiratory distress from Covid.
‘’So far, the results of the treatment with the drug MesenCure are extremely impressive and an improvement over the results of other treatments,’’ said Dr. Shadi Hamoud, the principal investigator in the clinical trials of the drugs.
Dr. Shadi said the results they have are so promising. The hospital had already started examining the use of the treatment for other indications.
Bonus reported on 10 Covid-19 patients between the ages of 45-75 who all had severe symptoms. 90% of them also had comorbidities. The released data showed a 40% decrease in lung inflammation from the treatment – from 55% to 15% as seen in chest x-rays.
This came in the first five days after treatment and a month later, lung inflammation had dropped to 1%.
They will continue the Phase II trial at Rambam and includes an additional 50 patients.
However, due to the low levels of infection in Israel, Bonus applied for approval to test the drug in Europe as well. The will complete this phase quickly once they fully enrol the remaining patients.
- At Least 115,000 Health Workers Have Died From Covid- WHO Chief
- 9 Vaccine Billionaires Arise Due To Covid-19
- WHO Announces More deadly Stage Of The Pandemic Yet To Set In
Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.